Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL

Nurix Therapeutics, Inc.

2025-Q2 EPS reported -$1.19 revenue$62,509,000

Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.
Net loss $43.5M ($0.52/sh) vs $44.5M ($0.71/sh) prior year; cash $485.8M.
Sanofi extended STAT6 license for $15M payment; total $127M received; up to $465M in milestones remain.
Bexobrutideg Phase 1 data: 80.9% ORR in r/r CLL including a complete response; favorable safety (no AFib, fungal infections).
FDA cleared IND for IRAK4 degrader GS-6791/NX-0479; pivotal CLL trial for bexobrutideg expects to start H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.